Catalog No.
KVV13501
Description
PRINCIPLE OF THE ASSAY
This assay employs the quantitative sandwich enzyme immunoassay technique. An antibody specific for Monkeypox Virus B6R has been pre-coated onto a microplate. Standards or samples are pipetted into the wells and any Monkeypox Virus B6R Antigen present is bound by the immobilized antibody. After washing away any unbound substances, a biotin-labeled antibody specific for Monkeypox Virus B6R is added to the wells. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of Monkeypox Virus B6R Antigen bound in the initial step. The color development is stopped and the intensity of the color is measured.
Specificity
MPXV B6R
Applications
Used for the quantitative determination of Monkeypox Virus B6R Antigen concentration in serum and plasma.
Detection method
Colorimetric
Sample type
Plasma, Serum
Assay type
Quantitative
Range
0.07 - 50 ng/mL
Sensitivity
0.05 ng/mL
Precision
Intra-Assay Precision (Precision within an assay): <10%
Three samples of known concentration were tested sixteen times on one plate to assess intra-assay precision.
Inter-Assay Precision (Precision between assays): <15%
Three samples of known concentration were tested in twenty four separate assays to assess inter-assay precision.
|
|
Intra-Assay Precision
|
Inter-Assay Precision
|
|
Sample
|
1
|
2
|
3
|
1
|
2
|
3
|
|
n
|
16
|
16
|
16
|
24
|
24
|
24
|
|
Mean (ng/mL)
|
15.7
|
5.1
|
1.4
|
15.9
|
5.5
|
1.5
|
|
Standard deviation
|
1.4
|
0.4
|
0.1
|
1.7
|
0.6
|
0.1
|
|
CV (%)
|
8.8
|
8.7
|
8.5
|
10.4
|
10.2
|
9.8
|
Recovery
80-120%
Shipping
2-8 ℃
Stability and Storage
When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%. For unopened kits, if you want to prolong the storage time, please store the Standard, Detection A, Detection B and Microplate at - 20 ℃, the rest reagents should be store at 4℃.
Generation and characterization of neutralizing antibodies against M1R and B6R proteins of monkeypox virus., PMID:40164599
Rational mpox vaccine design: immunogenicity and protective effect of individual and multicomponent proteins in mice., PMID:40105863
Immunogenicity of monkeypox virus surface proteins and cross-reactive antibody responses in vaccinated and infected individuals: implications for vaccine and therapeutic development., PMID:39994775
Development and validation of a quantitative Orthopoxvirus immunoassay to evaluate and differentiate serological responses to Mpox infection and vaccination., PMID:39987746
Long-Lasting Protection and Dose Optimization of MPXV Polyvalent Mpox mRNA Vaccines Against Lethal Vaccinia Virus Challenge in Mice., PMID:39726255
Immunoinformatics approach: Developing a multi-epitope vaccine with novel carriers targeting monkeypox virus., PMID:39679938
A penta-component mpox mRNA vaccine induces protective immunity in nonhuman primates., PMID:39639037
Programmable Macrophage Vesicle Based Bionic Self-Adjuvanting Vaccine for Immunization against Monkeypox Virus., PMID:39513669
Computational identification of monkeypox virus epitopes to generate a novel vaccine antigen against Mpox., PMID:39471737
Single-chain A35R-M1R-B6R trivalent mRNA vaccines protect mice against both mpox virus and vaccinia virus., PMID:39423738
Mpox global health emergency: Insights into the virus, immune responses, and advancements in vaccines PART II: Insights into the advancements in vaccines., PMID:39417768
Systematic evaluation of the induction of efficient neutralizing antibodies by recombinant multicomponent subunit vaccines against monkeypox virus., PMID:39321566
Analysis of binding and authentic virus-neutralizing activities of immune sera induced by various monkeypox virus antigens., PMID:38829493
Polyvalent mpox mRNA vaccines elicit robust immune responses and confer potent protection against vaccinia virus., PMID:38787725
In silico development of a novel anti-mutation, multi-epitope mRNA vaccine against MPXV variants of emerging lineage and sub-lineages by using immunoinformatics approaches., PMID:38450722
Evaluation and comparison of immune responses induced by two Mpox mRNA vaccine candidates in mice., PMID:37800627
Duration of humoral immunity from smallpox vaccination and its cross-reaction with Mpox virus., PMID:37709783
Examination of the cross-reactivity between vaccinia virus Tiantan strain and monkeypox virus., PMID:37473582
Mpox virus mRNA-lipid nanoparticle vaccine candidates evoke antibody responses and drive protection against the Vaccinia virus challenge in mice., PMID:37429529
Multi-valent mRNA vaccines against monkeypox enveloped or mature viron surface antigens demonstrate robust immune response and neutralizing activity., PMID:37300753
Development of multi-epitope vaccines against the monkeypox virus based on envelope proteins using immunoinformatics approaches., PMID:36993967
Rational development of multicomponent mRNA vaccine candidates against mpox., PMID:36947428
BoHV-4-Based Vector Single Heterologous Antigen Delivery Protects STAT1(-/-) Mice from Monkeypoxvirus Lethal Challenge., PMID:26086739
For research use only. Not for human or drug use.
